PDCD1 and hepatocellular carcinoma: Among these, there is the phase III study NCT03949231 that confronts the hepatic artery infusion with the vein infusion of toripalimab (monoclonal anti-PD1 Ab) in patients with (BCLC) C-stage hepatocellular carcinoma.